Insulin resistance is associated with hypercortisolemia in polynesian patients treated with antipsychotic medication

Diabetes Care

Volumn 30, Issue 6, 2007, Pages 1425-1429

  Poa, Nicola R ^a   Edgar, Paul F ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; CHOLESTEROL; GLOBULIN; GLUCOSE; HEMOGLOBIN A1C; HYDROCORTISONE; HYDROCORTISONE BINDING GLOBULIN; INSULIN; NEUROLEPTIC AGENT; SOMATOMEDIN C; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCORTISOLISM; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIA; INSULIN RESISTANCE; MALE; POLYNESIA; PSYCHOSIS; STATISTICAL SIGNIFICANCE; WAIST CIRCUMFERENCE;

ADULT; ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; CUSHING SYNDROME; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; NEW ZEALAND; POLYNESIA; PSYCHOTIC DISORDERS;

EID: 34249900177     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc06-2057     Document Type: Article

References (40)

1. Pharmac Annual Report 2005. Wellington, New Zealand, PHARMAC, New Zealand Government, 2005
2. Goldstein LE, Sporn J, Brown S, Kim H, Finkelstein J, Gaffey GK, Sachs G Stern TA: New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 40:438-443, 1999
3. Mahmoud R, Gianfransesco F, Grogg A Nasrallah H: Differential effects of antipsychotics on type II diabetes: findings from a large health plan database. In Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico. Washington, DC, American College of Cardiology, 2000
4. Goldstein LE Henderson DC: Atypical antipsychotic agents and diabetes mellitus. Primary Psychiatry 7:65-68, 2000
5. Thonnard-Neumann E: Phenothiazines and diabetes in hospitalized women. Am J Psychiatry 124:978-982, 1968
6. Simmons D, Thompson C Volklander D: Polynesians: prone to obesity and type 2 diabetes mellitus but not hyperinsulinaemia. Diabet Med 18:193-198, 2001
7. Simmons D, Gatland B, Fleming C, Leakehe L, Scragg R: Prevalence of known diabetes in a multiethnic community. NZ Med J 107:219-222, 1994
8. Recording Patient Information: Ethnicity. Wellington: New Zealand Health Information Strategy, 1996
9. Alberti K, Zimmet P: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1. Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539-553, 1998
10. Mathews D, Hosker J, Rudenski A, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419, 1985
11. Coolens J, Van Baelen H, Heyns W: Clinical use of unbound plasma cortisol as calculated from total cortisol and corticosteroid-binding globulin. J Steroid Biochem 26:197-202, 1987
12. Lewis J, Lewis M, Elder P: An enzyme-linked immunoassay for corticosteroid-binding globulin using monoclonal and polyclonal antibodies: decline in CBG following synthetic ACTH. Clin Chim Acta 328:121-128, 2003
13. Swinburn BA, Ley SJ, Carmichael HE, Plank LD: Body size and composition in Polynesians. Int J Obes Relat Metab Disord 23:1178-1183, 1999
14. Knowler WC, Pettitt DJ, Saad MF, Bennett PH: Diabetes mellitus in the Pima Indians: incidence, risk factors and pathogenesis. Diabetes Metab Rev 6:1-27, 1990
15. Grieco E: The Native Hawaiian and Other Pacific Island Populations. Washington, DC, U.S. Department of Commerce, 2000
16. Cadwell J, Missingham B, Mardk J: The Population of Oceania in the Second Millennium. Canberra, Australia, Australian National University, 2001
17. Isomaa B, Henricsson M, Almgren P, Tuomi T, Taskinen MR, Groop L: The metabolic syndrome influences the risk of chronic complications in patients with type II diabetes. Diabetologia 44:1148-1154, 2001
18. Kannel WB, McGee DL: Diabetes and cardiovascular disease: The Framingham Study. JAMA 241:2035-2038, 1979
19. Wingard DL, Barrett-Connor E, Criqui MH, Suarez L: Clustering of heart disease risk factors in diabetic compared to non-diabetic adults. Am J Epidemiol 117:19-26, 1983
20. Patel A: Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation 110:2678-2686, 2004
21. Weyer C, Foley JE, Bogardus C, Tataranni PA, Pratley RE: Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts type II diabetes independent of insulin resistance. Diabetologia 43:1498-506, 2000
22. Ford ES: Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 28:1769-1778, 2005
23. Ebenbichler CF, Laimer M, Eder U, Mangweth B, Weiss E, Hofer A, Hummer M, Kemmler G, Lechleitner M, Patsch JR, Fleischhacker WW: Olanzapine induces insulin resistance: results from a prospective study. J Clin Psychiatry 64:1436-1439, 2003
24. Mackay J: Effective mental health policy for Maori. HRC Newsl, No., 28, p. 5, 1999
25. Meyer JM, Pandina G, Bossie CA, Turkoz I, Greenspan A: Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study. Clin Ther 27:1930-1941, 2005
26. Dallman MF, Strack AM, Akana SF, Bradbury MJ, Hanson ES, Scribner KA, Smith M: Feast and famine: critical role of glucocorticoids with insulin in daily energy flow. Front Neuroendocrinol 14:303-347, 1993
27. Ryan MC, Collins P, Thakore JH: Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 160:284-289, 2003
28. Cohrs S, Pohlmann K, Guan Z, Jordan W, Meier A, Huether G, Ruther E, Rodenbeck A: Quetiapine reduces nocturnal urinary cortisol excretion in healthy subjects. Psychopharmacology (Berl) 174:414-420, 2004
29. le Roux CW, Sivakumaran S, Alaghband-Zadeh J, Dhillo W, Kong WM, Wheeler MJ: Free cortisol index as a surrogate marker for serum free cortisol. Ann Clin Biochem 39:406-408, 2002
30. Folli F, Saad MJ, Kahn CR: Insulin receptor/IRS-1/PI 3-kinase signaling system in corticosteroid-induced insulin resistance. Acta Diabetol 33:185-192, 1996
31. Saad MJ, Folli F, Kahn JA, Kahn CR: Modulation of insulin receptor, insulin receptor substrate-1, and phosphatidylinositol 3-kinase in liver and muscle of dexamethasone-treated rats. J Clin Invest 92:2065-2072, 1993
32. Ader M, Kim SP, Catalano KJ, Ionut V, Hucking K, Richey JM, Kabir M, Bergman RN: Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes 54:862-871, 2005
33. Sesti G, Sciacqua A, Cardellini M, Marini MA, Maio R, Vatrano M, Succurro E, Lauro R, Federici M, Perticone F: Plasma concentration of IGF-I is independently associated with insulin sensitivity in subjects with different degrees of glucose tolerance. Diabetes Care 28:120-125, 2005
34. Moses AC, Young SC, Morrow LA, O'Brien M, Clemmons DR: Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes 45:91-100, 1996
35. Howes OD, Gaughran FP, Amiel SA, Murray RM, Pilowsky LS: The effect of clozapine on factors controlling glucose homeostasis. J Clin Psychiatry 65:1352-1355, 2004
36. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T: Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288-1295, 2002
37. Qi Y, Takahashi N, Hileman SM, Patel HR, Berg AH, Pajvani UB, Scherer PE, Ahima RS: Adiponectin acts in the brain to decrease body weight. Nat Med 10:524-529, 2004
38. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA: Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:1930-1935, 2001
39. Hosojima H, Togo T, Odawara T, Hasegawa K, Miura S, Kato Y, Kanai A, Kase A, Uchikado H, Hirayasu Y: Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia. J Psychopharmacol 20:75-79, 2006
40. Togo T, Kojima K, Shoji M, Kase A, Uchikado H, Katsuse O, Iseki E, Kosaka K: Serum adiponectin concentrations during treatment with olanzapine or risperidone: a pilot study. Int Clin Psychopharmacol 19:37-40, 2004